Campbell & CO Investment Adviser LLC Takes Position in Fulcrum Therapeutics, Inc. $FULC

Campbell & CO Investment Adviser LLC acquired a new position in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 102,470 shares of the company’s stock, valued at approximately $943,000. Campbell & CO Investment Adviser LLC owned 0.19% of Fulcrum Therapeutics as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the stock. Simplify Asset Management Inc. increased its holdings in Fulcrum Therapeutics by 13.8% during the 3rd quarter. Simplify Asset Management Inc. now owns 83,234 shares of the company’s stock worth $766,000 after purchasing an additional 10,080 shares in the last quarter. Farther Finance Advisors LLC grew its holdings in shares of Fulcrum Therapeutics by 108.3% during the third quarter. Farther Finance Advisors LLC now owns 7,112 shares of the company’s stock worth $65,000 after buying an additional 3,697 shares in the last quarter. Evergreen Capital Management LLC acquired a new stake in Fulcrum Therapeutics in the 2nd quarter valued at approximately $114,000. LMR Partners LLP bought a new stake in Fulcrum Therapeutics in the 2nd quarter valued at approximately $344,000. Finally, Balyasny Asset Management L.P. acquired a new position in Fulcrum Therapeutics during the 2nd quarter worth approximately $9,207,000. 89.83% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Fulcrum Therapeutics news, major shareholder Ra Capital Management, L.P. sold 4,175,139 shares of Fulcrum Therapeutics stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $13.98, for a total value of $58,368,443.22. Following the completion of the sale, the insider owned 6,053,960 shares in the company, valued at $84,634,360.80. The trade was a 40.82% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Robert J. Gould sold 15,000 shares of the stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $11.87, for a total transaction of $178,050.00. Following the transaction, the director owned 469,864 shares in the company, valued at approximately $5,577,285.68. The trade was a 3.09% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 4,205,139 shares of company stock worth $58,711,943. Insiders own 7.00% of the company’s stock.

Fulcrum Therapeutics Stock Performance

Shares of FULC stock opened at $10.14 on Tuesday. Fulcrum Therapeutics, Inc. has a 52 week low of $2.32 and a 52 week high of $15.74. The company has a market capitalization of $548.78 million, a price-to-earnings ratio of -8.59 and a beta of 3.20. The company has a 50-day simple moving average of $10.94 and a 200 day simple moving average of $8.90.

Fulcrum Therapeutics (NASDAQ:FULC) last issued its quarterly earnings data on Wednesday, October 29th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.02). Sell-side analysts forecast that Fulcrum Therapeutics, Inc. will post -0.16 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on FULC. Stifel Nicolaus set a $25.00 price objective on shares of Fulcrum Therapeutics in a report on Monday, December 8th. Cantor Fitzgerald lifted their price target on shares of Fulcrum Therapeutics from $15.00 to $24.00 and gave the company an “overweight” rating in a research note on Monday, December 8th. Bank of America boosted their price target on shares of Fulcrum Therapeutics from $6.00 to $7.00 and gave the stock an “underperform” rating in a research report on Tuesday, December 9th. Citigroup restated an “underperform” rating on shares of Fulcrum Therapeutics in a report on Monday, December 8th. Finally, HC Wainwright lifted their target price on Fulcrum Therapeutics from $18.00 to $25.00 and gave the company a “buy” rating in a research report on Monday, December 8th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $19.11.

Fulcrum Therapeutics Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.